Pharma Journalist

6th Dermatology Drug Development Summit
2022-11-01 - 2022-11-03 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
The 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases returns to Boston this fall.
Ensure you join this year’s 150+ expert community in-person to:

Uncover recent studies evaluating critical inflammatory and auto-immune pathways
Gain a deeper understanding of promising biologics targeting IL-13, IL-31, IL-33, versus IL-17 associated diseases
Assess emerging efficacious targeted approaches in the plethora of conditions outside of these pathways.
Obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet needs such as Hidradenitis Suppurativa, Vitiligo, Rare Disease, and Alopecia Areata

View the event program here: https://ter.li/g3z67z
Register here: https://ter.li/vu3tx9
If you have any further questions regarding the summit, please contact us at info@hansonwade.com.

6th Microbiome Movement – Human Nutrition Summit
2022-11-07 - 2022-11-09 | TBC
Returning to Boston for 2022, the 6th Microbiome Movement- Human Nutrition Summit is the only industry focused meeting dedicated to exploring the latest innovations, practical applications and clinical benefits of microbiome targeting food, beverages and supplements to pave the route to commercial success in the consumer health setting.
Get up to speed on this dynamic industry with expertise shared from the likes of Bayer, Postbiotics Plus, Amazentis and many others, as the titans of industry unite to:

Showcase the latest scientific findings on the mechanism and functional role of novel microbiome targeting ingredients
Shine a spotlight on the future of postbiotics, and advance commercialization of microbiome-targeted nutritional interventions
Advance commercialization of microbiome-targeted nutritional interventions

With consumers demanding to have greater control over personal health and wellbeing, join your community of 100+ industry experts from global CPG companies, innovative start-ups and biotechs to usher in a new wave of personalised nutrition.
To know more visit: https://bit.ly/3clIDZQ

6th Antifibrotic Drug Development Summit (AFDD)
2022-11-09 - 2022-11-11 | Crowne Plaza Woburn, 15 Middlesex Canal Park Rd, Woburn, MA, 01801, United States
Returning for the 6th year, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF, NASH, CKD and more in one place at one time, so you can advance the progress of your antifibrotic therapies.
From exploring cellular mechanisms to identify a common fibrotic pathway to bridging the translational gap to prove early therapeutic effectiveness; this unique cross-organ, cross-disease, cross-discipline discussion forum is here to transform your fibrosis research.
Join 100+ industry super giants from Boehringer Ingelheim, Genentech, Gilead, Pfizer, Novartis, and many more in Boston to harness the knowledge you need for your 2022/23 antifibrotic research and drug development.
To know more visit: https://ter.li/u60ni5

Medical Devices and IVD 2022
2022-11-14 - 2022-11-15 | London, UK
SAE Media Group’s Inaugural Conference…
Medical Devices and IVD 2022
14 – 15 November 2022
London, UK
www.medicaldevices-ivd.com/PJ
Navigating The MDR and IVDR and Best Strategies for Compliance
SAE Media Group is proud to announce the launch of the Medical Devices and IVD Conference, taking place on 14 – 15 November 2022 in London, UK.

The MDR implementation last May has highlighted issues within the industry that need to be addressed and the upcoming IVDR updates will have a profound impact on the medical device industry, bringing certain products into regulatory scope that were previously excluded, introducing new manufacturing requirements, and increasing the burden for post-market surveillance.
The conference will provide insight into the latest updates in EU MDR and IVDR regulations and will discuss strategies for how to best comply with these regulations. In addition, the conference will consider the evolving regulatory landscape for digital health software.
BENEFITS OF ATTENDING:

Engage with notified body and competent authority representatives addressing key MDR and IVDR requirements
Gain insights from pharma regulatory experts in compliance and companion diagnostics
Understand the latest guidance on IVD Regulations to overcome common challenges, in addition to considering evolving global regulations
Examine post-market expectations for surveillance and vigilance of your medical devices
Delve into advancements in the digitalisation of medical devices and the regulatory considerations surrounding this

WHO SHOULD ATTEND:
Executives, Directors, VPs, Heads, Principals, Managers of:

Device Manufacturing
Regulatory Affairs
IVDR
MDR
CMC
Compliance
Risk Management
Traceability
Vigilance
Product Development
PFS
Combination Products

To find out more, please visit: www.medicaldevices-ivd.com/PJ
EARLY BIRD RATES:

BOOK BY 30TH JUNE TO SAVE £200
BOOK BY 30TH SEPTEMBER TO SAVE £100

ADDITIONAL CONTACT INFORMATION:

E: ngaloria@smi-online.co.uk
T: +44 (0) 20 7827 6164

FOLLOW US ON:

Twitter: @SAEMGPharma

LinkedIn: SAE Media Group Pharma

Microbiome Connect: USA 2022
2022-11-16 - 2022-11-17 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development platforms applying microbes, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis. As the first FDA approved microbiome-targeted therapeutic emerges, drug developers will have the opportunity to benchmark their rational drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications. Furthermore, the manufacturing challenges associated with reaching commercialization specific to microbiome-based drugs will be addressed in depth. With talks from Live Biotherapeutic Product manufacturing experts, including the Head of CBER, on topics including how to handle USP 61/62, and achieving co-culturing capabilities. Join us to hear from microbiome biotechs, pharma voices, investment bodies, and more on how to develop robust, scalable, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market.
To know more visit: www.microbiomeconnectusa.com

Liquid Biopsy Surveillance & Early Detection Summit
2022-11-16 - 2022-11-17 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
Recognize Disease Hallmarks Earlier for Improved Patient Outcomes
Gain Clarity Across Next Generation Non-Invasive Testing Technologies Revolutionizing Cancer Monitoring, MRD & Earlier Detection to Support Novel Pre-Metastatic Drug Development with Maximized Access
In the wake of new FDA guidance and exciting MRD partnership announcements between Grail & AstraZeneca, Amgen & Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift. Touted as having the potential to transform clinical practice as we know it, technical progress and mounting investment in premetastatic applications are creating huge industry-wide excitement for liquid biopsy-based screening & surveillance for novel precision drug development.
With technology maturity on the near horizon, the inaugural Liquid Biopsy Surveillance & Early Detection Summit is your only dedicated platform providing much-needed clarity on the industry’s emerging assays increasingly opening the doors to novel trial design and better patient outcomes.
As drug & diagnostic developers look to realize the commercial impact of early detection & MRD while shifting pipelines from the metastatic setting, here lies your best opportunity to harness game-changing technologies to define leading stratification, surrogate endpoint, and regulatory strategies – accelerating the delivery of breakthrough therapies into the clinic.
Providing a path forward for early detection & surveillance to become a widespread patient reality, unite with 80+ Translational, Biomarker, Clinical, Regulatory, Precision Medicine, Medical Affairs & Diagnostic experts at your only forum prioritizing liquid biopsy applications for earlier intervention.
To know more visit: https://ter.li/0kjtfi

4th Annual Gene Therapy Analytical Development Summit 2022
2022-11-28 - 2022-12-01 | Westin Boston Seaport, 425 Summer Street, Boston, MA, 02210, United States
The past twelve months have culminated in an unprecedented level of excitement, investment, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy, in the context of increased regulatory scrutiny and safety challenges, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important.
This year’s summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech, pharma and academia to continue to develop resilient, long-lasting and robust analytical tools to enhance the safety, quality and efficacy of gene therapy products.
Whether you are focusing on specific characterization methods, enhancing your genome sequencing, advancing your understanding of full and partial particles, or advancing your early-stage bioassays, with 4 tracks, 8 pre-conference workshops and a post-conference focus day, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development, giving you the chance to address and overcome challenges.
If you work in quality control, quality assurance, or process development – we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments, bridging between analytical methods with regards to QC/PD, and enhancing in-process development support.
Whether you’re working with AAV, non-viral vectors or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.
To know more visit: https://ter.li/w2diiu

2nd Rare CNS & Neurodevelopmental Drug Development Summit
2022-11-28 - 2022-11-30 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
Developing New Outcome Measures, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare, Genetic CNS Disorders
With more clinical data emerging, neurodevelopmental drug development is advancing from hypotheticals to real-life clinical results, outcomes, and functional biomarkers, catapulting this critical field forwards.
Join 100+ peers this November at the 2nd Rare CNS & Neurodevelopmental Drug Development Summit – the only industry dedicated drug development forum for large pharma, biotech, academia, and patient advocacy groups, paving the way towards symptomatic and successful disease modifying treatments.
Tightly focused on industry progress, stakeholders will explore ASOs, gene therapies and small molecules across autistic syndromes and seizure phenotypes at this unique drug sponsor conference.
Don’t miss out on this definitive opportunity to collaborate with patient groups and gain regulatory clarity on clinical trial design, endpoints and delivery and toxicity concerns as well as deep diving into functional and molecular biomarkers, emerging therapeutic targets and translational biology.
If you are working towards treatments for rare CNS and neurodevelopmental disorders, including (but not limited to) Angelman Syndrome, Rett syndrome, Fragile X, Dravet Syndrome and CDKL5 Syndrome or discovering new frontiers in anti-epileptic therapeutics, this is the platform you need.
To know more visit: https://ter.li/9yzux5

4th Inflammasome Therapeutics Summit
2022-11-29 - 2022-12-01 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
The 4th Inflammasome Therapeutics Summit is the only industry-led forum uniting large pharma, biotechs, and academic KOLs, with the common goal of accelerating the practical translation and clinical development of inflammasome-targeted drugs, which are shaking up the immunology R&D landscape.
As the space eagerly awaits data readouts from proof-of-concept trials, and with more companies than ever before with active inflammasome therapeutic pipelines; this is your opportunity to be involved in interactive discussions on:

Deciphering the intricate mechanisms underlying dysregulated inflammasome signaling within the wider context of the immune system
Overcoming limitations of preclinical models, identifying clinically meaningful biomarkers of inflammasome inhibition, and defining good clinical endpoints
Taming inflammation and achieving optimized safety profiles using the next frontier for inflammasome-targeted drugs including those targeting NLRP3 and novel targets
Delving into specific disease groups to demonstrate where inflammasome therapeutics will be most impactful

Join 120+ fellow peers and industry heavyweights this Fall including NodThera, Novartis, Zyversa Therapeutics, and more, to build meaningful partnerships and propel the next frontier of inflammasome therapeutics from pipeline development into a clinical and commercial reality.
Access the official event guide here to learn more.

6th Obesity & NASH Drug Development Summit
2022-11-29 - 2022-12-01 | Revere Boston Common, 200 Stuart St, Boston, MA, 02116, United States
The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders.

With mounting competition for the market in obesity and all eyes on the next wave of NASH candidates, the 6th Obesity & NASH Drug Development Summit, (previously the NASH Summit) is dedicated to reuniting industry leaders in metabolic syndrome to consolidate targets directly implicated in disease pathology and traverse the regulatory hurdles to commercialization.
Join 150+ industry pioneers in Boston including pioneers Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Pfizer, Inventiva, Regeneron, FDA, AstraZeneca, and more to advance your pipeline towards approved treatment.
Access the official event guide here to learn more.

3rd CRISPR 2.0 Summit
2022-11-29 - 2022-12-01 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Recognized with a Nobel Prize in 2020, CRISPR has opened the floodgates for a new era of gene editing therapies, promising to transform genetic disease treatments. With a well-established early field of genomics research, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit, including Cas nucleases, base and prime editing technologies, and innovative delivery platforms.
The 3rd CRISPR 2.0 Summit is devoted to showcasing the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy, minimizing off-target effects & enabling efficient tissue-specific delivery to help you progress your program into and through the clinic.
Across three days of content, co-designed with 27+ industry thought leaders, this streamlined one-track summit will unite 100+ key players in the CRISPR space, from large pharma to ground-breaking biotech, academics to exciting service providers, all with the purpose of paving a way forward to market for your CRISPR gene editing program.
Here’s a snapshot of our 27+ thought leaders:

Kiran Musunuru, Professor of Medicine, Perelman School of Medicine, University of Pennsylvania
Amy Simon, Chief Medical Officer, Beam Therapeutics
Jane Grogan, Chief Scientific Officer, Graphite Bio
Liron Walsh, Head of Development; In Vivo Programs, Intellia Therapeutics
Jeremy Duffield, Chief Scientific Officer, Prime Medicine
Eric B. Kmiec, Executive Director & Chief Scientific Officer, Christiana Care Gene Editing Institute
Rafi Emmanuel, Senior Vice President – Research & Development, Emendo Biotherapeutics
John Murphy, Chief Scientific Officer, Arbor Biotechnologies
Inge Yung-Chih Cheng, Principal Scientist, Pfizer
Joey Riepsaame, Head of Genome Engineering, University of Oxford
Rammohan Devulapally, Principal Scientist, GenEdit

Be part of the community as we dive deep into:

Refining non-viral tissue targeted CRISPR delivery methods for maximized safety and efficacy, with help from GenEdit and the latest research from the David Liu Lab.
From bench to bedside: translating basic CRISPR research into a viable therapeutic product, with Beam Therapeutics
Leverage the latest base and prime editing technology for enhanced precision treatment of inherited disorders, with Prime Medicine and UC Irvine.

And more!
Join this unmissable summit and network experts from the likes of Beam Therapeutics, The David Liu Lab, Pfizer, GenEdit, AZ, GSK, Caribou Biosciences, Prime Medicine, Intellia Therapeutics and many more.
To know more visit: https://ter.li/vumobp

PAT & Real Time Quality Summit
2022-12-01 - 2022-12-02 | Hilton San Diego Gaslamp Quarter, 401 K Street, San Diego, CA, 92101, United States
The time has come to remove the pharmaceutical industry’s reliance on archaic off-line testing and embrace the cost and speed-to-market savings of online control and real-time product quality.
The PAT market is projected to reach USD 4.96 Billion by 2027, spurred on by the recent ICH Q14/ Q2 (R2) guidelines, there has never been a more opportune moment to leverage regulator’s support of QbD, real-time control, and process intervention to achieve meaningful business impact in your organization, through reduced downtime, manufacturing footprint, ease of scale-up and product consistency for approval.
Whether you’re applying in small molecules, biologics, or ATMP, bridge the gap in technology, culture, or regulatory experience that is the bottleneck to your organization saving an average 50% reduction in process cycle time and winning speed to market, with the strategical implementation of smart process analytical technologies and quality by control (QbC).
Join a senior community of experts in process development, manufacturing, regulatory & quality to understand how to monitor critical quality attributes with reactive and predictive control systems and discover novel PAT technologies as the industry moves the needle toward realizing real-time release.
To know more visit: https://ter.li/080rbc

4th Annual Gene Therapy for Neurological Disorders
2022-12-05 - 2022-12-08 | The Westin Seaport District, 425 Summer St, Boston, MA, 02210, United States
Delivering the Next Wave of Gene Therapies to the CNS
With systemic toxicity challenges plaguing the AAV field, direct administration for CNS indications creates an ideal target for gene therapy. This is an exciting year for the neurological space with clinical data to show and new biotechs coming out of the woodwork to release the next wave of gene therapies with more advanced CNS targeting for a wider selection of neurological targets.
The 4th Annual Gene Therapy for Neurological Disorders Summit will unite gene therapy developers with an industry-focused agenda across 4 days and 2 dedicated tracks of content to solve the preclinical, translational and clinical challenges of targeting a wide range of neurodevelopmental and neurodegenerative disorders with both ‘first’ and ‘next’ generation gene therapies.
Join the expanding audience of gene therapy experts to:

Streamline CNS drug delivery devices for improved brain biodistribution
Discover novel vectors for CNS specificity & tropism
Optimize gene therapy strategy for pediatric & adult neurological disorders

To know more visit: https://ter.li/rluqrj

4th Annual Cell Therapy Analytical Development Summit
2022-12-05 - 2022-12-07 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Cell Therapy Analytical Development Summit US is back for its fourth year, taking place in Boston (December 5-7). Join 180+ colleagues from analytical development, process development, quality control and regulatory affairs, to standardize analytical testing and take advantage of unrivalled content across:

3-days
6 deep-dive workshops
2 tracks

Seize an unmatched opportunity to delve into cell potency, safety, viability, sterility and more across both autologous and allogeneic cell therapy products.
Please use this URL – https://ter.li/ghwxjk

5th Commercializing Clinically Validated Digital Therapeutics Summit
2022-12-06 - 2022-12-08 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
The 5th Commercializing Clinically Validated Digital Therapeutics Summit, designed with DTx companies, pharma and clinicians, will return this December to address the industry’s major challenges such as improving user experience, clinical trial development, and standing out in a crowded market through open discussion and case-study led presentations.
Whether you’re a veteran at commercializing clinically validated digital therapeutics, looking for partnerships, or a new entrant to the field, you’ll leave this conference with practical lessons and essential connections needed to supercharge DTx commercial ambitions across 2022 and beyond.
To know more visit: https://ter.li/5e6hqd

4th Annual Targeted Radiopharmaceuticals Summit Europe
2022-12-06 - 2022-12-08 | Leonardo Royal Amsterdam, Paul van Vlissingenstraat 24, Amsterdam, 1096 BK, Netherlands
The long-awaited 4th Annual Targeted Radiopharmaceuticals Summit Europe is returning in-person in Amsterdam on December 6-8, 2022!
As the only devoted meeting for large pharma, biotech and pioneering academics, this meeting unites key stakeholders under the mutual and ambitious objective of advancing radioligand candidates to commercialisation through rigorous clinical rationale and reliable supply chain design.
Download the full Event Guide to learn what the 29+ expert speakers will present on, including:

Meeting the newest contenders to enter the field including Ariceum Therapeutics and TRIMT
Discovering new targeting systems that are opening avenues to treating more cancers with Tagworks and Ratio Therapeutics
Getting the most up-to-date information on current radionuclide stocks and how the world’s leading isotope producers are increasing their production and variety of products with Duke University
Enhancing your trial design to conduct the most rigorous trials with help from leading clinical stage companies with Oncoinvent
The ability to showcase your work and meet new people across dedicated sessions and have the meetings that will help you build vital collaborations

Access the official Event Guide here to see the complete agenda and speaker line up.

2nd Next-Generation Food Allergy Drug Development Summit
2022-12-06 - 2022-12-07 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The field of food allergy therapeutics is continuing to boom as companies flood the news with fresh IND clearances and clinical readouts. The race to market for the next food allergy therapy is well and truly on, but access to funding and large patient cohorts, along with the need for novel IgE biomarkers and better diagnostics (to name a few challenges) are holding drug developers back from even faster progress.
The 2nd Next-Generation Food Allergy Drug Development Summit is reuniting this December as the only industry-focused meeting dedicated to unveiling the complexities of food allergies with novel oral immunotherapies, antibody-based therapeutics and microbiome-based approaches to accelerate ground-breaking treatments for the ever-increasing unmet medical need.
Join us in-person for the first time in Boston as the food allergy community comes together to unravel the complex regulatory landscape, identify and validate novel clinical biomarkers to aid patient selection and explore novel routes of administration to innovate long-lasting, next-generation treatments.
To know more visit: https://bit.ly/3GlzzRp

3rd TIGIT Axis Therapies Summit
2022-12-07 - 2022-12-08 | Digital Event
In the context of a need to regroup and accelerate practice-changing cancer immunotherapies towards approval and to patients in need, the 3rd TIGIT Axis Therapies Summit returns to reunite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor, blood cancer and non-oncology setting.
Covering deciphering the mechanistic intricacies underlying TIGIT axis signaling, defining combination partners that improve efficacy and strengthen TIGIT targeted pipelines, exploring novel drug designs in terms of Fc functionality and IgG type, identifying molecular signatures relevant to the tumor microenvironment and periphery to incorporating unique pharmacology properties into trial design, this is your comprehensive guide for addressing the unique challenges of TIGIT axis targeted drug development and powering up your pipelines.
This year’s sharp two-day agenda leans into the clinical headwinds faced by so many immune checkpoint targets. As the space regroups, join the conversation to build meaningful partnerships and maximize the clinical and commercial success of the next generation of TIGIT axis targeted drugs.
Find out more here: https://ter.li/ir0syg

5th Annual RNA-Targeted Drug Discovery Summit
2022-12-13 - 2022-12-15 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
RNA-Targeted Drug Discovery Summit returns for its fifth year this December. Join the summit for deep dive into new and emerging topics such as:

Induced Proximity as a new class of “targeted RNA degraders”
Next-generation probing and screening technologies to accelerate HIT identification and validation
Biophysical, biochemical, and cell-based assay development strategies to identify and optimize small molecules interacting with RNA
In vivo pharmacology, safety, and efficacy early considerations to accelerate the transition from discovery to pre-clinical and clinical development

View the event program here: https://ter.li/7qs017
Secure your place here: https://ter.li/jlh128
If you have any further questions regarding the summit, please contact us at info@hansonwade.com.

2nd Synthetic Biology-Based Therapies Summit
2022-12-13 - 2022-12-15 | (exact venue TBC), Boston, US.
Returning for a second year the Synthetic Biology-Based Therapies Summit is the leading industry-defining forum made exclusively for leaders in the synthetic and engineered biology space, focusing on the technical challenges that lie ahead in the path towards commercialization.
Download the event guide to find out more
Learn from industry trailblazers at Arsenal Biosciences, bit.bio, Moderna, MIT, Novome Bio, Strand Therapeutics, Synlogic and more, to support your efforts in developing safe and effective synthetic biology-based therapeutics.
Join Global Innovators to:

Learn from the academics that are driving the future of synthetic biology development with the National Institute of Standards & Technology and Massachusetts Institute of Technology
Leverage novel control strategies for improved therapeutic efficacy and patient safety with Arsenal Biosciences, bit.bio, CHAIN Biotechnology and Strand Therapeutics
Employ synthetic biology techniques in the clinic, hearing about a variety of therapeutic applications with Kite Pharma: A Gilead Company, Novome Biotechnologies and Senti Biosciences
Apply computation, artificial intelligence, and machine learning to engineered and synthetic biology with Lawrence Berkley National Laboratory and Sanofi
Explore the potential for engineered biology as a tool for drug discovery and development with LifeMine Therapeutics and Merck & Co.

Advanced Wound Care Summit Europe 2022
2022-12-13 - 2022-12-14 | TBC, Berlin, Germany
The Advanced Wound Care Summit EU is the first industry-led, EU-focused, forum on commercialising innovative wound care products. How will you comply with the EU MDR? What is the best strategy to ensure widespread clinical adoption and reimbursement? What can you do to engage with other wound care companies, for collaboration or acquisition? Expect to hear from, and network with, wound care leaders, across large wound care companies and SMEs.
Find out how C-level Executives, VPs and Directors of R&D are tackling the most pressing industry challenges, seizing growth opportunities, and building innovation. Whether an executive, investor, researcher or healthcare professional, this meeting offers an empowering environment that allows you to secure your stake in the AWC market.
To know more visit: https://hubs.ly/Q01lR8NX0

PURIFY – Chromatography Purification Conclave
2022-12-14 | Taj Skyline, Ahmedabad
PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities, be it discovery, development or scaleups!
The pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification.
The attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches, niche topics, deeper understanding of preparative and process chromatography and allied fields, and upcoming application areas that will provide quality substance to the discerning scientists. So, if you wish to get that additional gram, which is purer, in as less a time, with minimal resources…there will surely be something for you at PURIFY conclaves!
The annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP, a Mumbai based company.
The PURIFY conclave is attended by analytical and research chemists, scientists with scale-up and process development knowledge, managers, group heads, natural product purification experts, experts from quality and manufacturing, academicians, policy makers, supply chain heads etc. of this pharmaceutical – APIs, peptides, proteins, oligonucleotides, chiral molecules, bio-pharmaceutical, fine chemicals, environmental studies, food and beverage, polymers, biotechnology, cosmetics and fragrance to understand the advancements in chromatography platforms.
So, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related.

Pre-Filled Syringes and Injectable Drug Devices Europe
2023-01-10 - 2023-01-12 | London, UK
SAE Media Group’s 15th Annual Conference
Pre-Filled Syringes and Injectable Drug Devices Europe
January 10 – 12 2023 | London, UK
http://www.pre-filled-syringes.com/pharmajournalist
————————————————————————-
The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to increase patient centricity, aid self-administration and deliver biologics that have large-volumes and novel formulations. This year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma, device developers and regulators can work together to encourage innovation.

SAE Media Group’s 15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference will be bigger than ever, with a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference comprising of morning keynote plenaries and parallel afternoon topic streams as detailed below:

Novel Drug Products and Large Volume Delivery
Sustainability for Injectable Delivery Devices
Primary Packaging Development
Connected Drug Delivery Devices

Topics of discussion will include the latest updates in the combination product regulatory framework, insights into the evolving digital health landscape for connected delivery devices, considerations for the development of primary packaging, utilising platform technology, the delivery of novel drug formulations and large volume drug products, patient centric approaches to device design as well as sustainable approaches for device development.
This event will not only bring you key insights you need to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry.
Benefits of Attending:

Engage with industry representatives on the latest trends within the pre-filled syringe and injectable device market
Hear about new technological advances in the delivery of large volume drugs
Explore updates to drug device combination product design approaches considering patient preference at the forefront with case studies from big pharma representatives
Understand the latest regulatory requirements from regulatory experts surrounding medical devices and digital health
Delve into the considerations for material components for the development of primary packaging
Gain insight into how big pharma are incorporating sustainable approaches into drug device design

Who should attend:
Advanz Pharma; AstraZeneca; Balda Medical GmbH & Co. KG; Bayer AG; Bayer Pharma; BD Medical; BD Medical – Pharmaceutical Systems; Becton Dickinson (BD); Boehringer Ingelheim; Boehringer Ingelheim GmbH & Co. KG; Boehringer Ingelheim Pharma GmbH & CO KG; Boehringer Ingelheim Pharma Gmbh & Co. Kg; BSI; BSI Group; Chiesi Ltd; Crux Product Design Ltd; DCA Design International; Device Development; Dr.Reddys; GlaxoSmithKline; GSK; Hoffmann-La Roche; Horizon Therapeutics GmbH; Ichnos Sciences; Janssen Pharmaceutical Companies; Johnson & Johnson; Johnson & Johnson (Janssen Pharmaceutical); Medincell; Merck Group; Midas Pharma Gmbh; Nemera; Novartis; Novo Nordisk; Novo Nordisk A/S; Owen Mumford; Pfizer; Pfizer UK; PharmaEssentia; Prescient Healthcare Group; RAUMEDIC AG; Sanofi; SCHOTT AG; SPM MEDICARE PVT LTD, INDIA; Sustainable Healthcare Coalition; Takeda; Teva; Teva Pharmaceuticals; Teva Pharmaceuticals Industries Ltd.; Teva, Combination Products; TUV Italia SRL; TUV SUD Japan Ltd.; TUV SUD Product Service GmbH; University of Liverpool; University of Southern Denmark; Zeon Europe GmbH; Zeon Specialty Materials ;
SAE Media Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages.
For details, please contact Daniele Moreschi on: +44 (0)20 7827 6050 or dmoreschi@smi-online.co.uk
For all delegate enquiries, contact Jamie Wilkinson on: +44 (0) 20 7827 6136 or jwilkinson@smi-online.co.uk
About SAE Media Group Conferences:
SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences. http://www.smgconferences.com
SAE Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.

11th Annual Pharmaceutical Microbiology Conference
2023-01-16 - 2023-01-17 | London, United Kingdom
11th Annual Pharmaceutical Microbiology Conference
16 – 17 January 2023
London, UK
http://www.pharma-microbiology.com/PJwl
Sponsored by: Microgenetics
Co-chairs Di Morris, Clinical Auditor, AstraZeneca and Nigel Cryer, Deputy Director Global Audit, Sanofi
Harnessing Alternative Rapid Microbial Methods for a Successful Contamination Control Strategy

We are delighted to announce SAE’s 11th Annual Pharmaceutical Microbiology Europe Conference taking place in London, UK on the 16-17 January 2023.
Microbiology remains an essential tool for the detection of microorganisms present in biopharmaceutical and pharmaceutical batches. This conference will explore the most pressing topics in this thriving field, from the movement toward process automation and increased regulatory stringency, to the latest technologies in rapid microbiological testing methods and data integrity.
Event Hashtag: #MicrobiologyEurope
Key Highlights for 2023 Conference:

Optimise your contamination control strategy and review the initial impact of Annex 1
Learn how to utilise the latest microbiological methods to modernise your contamination control strategy
Maximise the data output from your environmental and microbial monitoring with proven strategies and technologies
Increase the diversity of your testing methodologies through industry case studies including the recombinant factor C assay and Monocyte Activation Test

Who Should Attend?
Heads of Microbiology, Heads of Aseptic Processing, Global Quality Directors, Heads of GMP Compliance, Quality & Compliance Heads, Microbiology Senior Specialists, Directors of Quality Control Biology, Quality Control Managers, Quality Assurance Managers, Lean Managers, Operations Managers, Heads of Site Compliance, Heads of Sterile Technology, Global Microbiology Analytical Experts, Cleanroom Managers, Regulatory Affairs Managers, Production Managers, Quality Systems Managers
Download the brochure at: http://www.pharma-microbiology.com/PJwl

Spatial Biology for Immuno-Oncology Summit
2023-01-17 - 2023-01-19 | The Westgate Hotel, 1055 2nd Ave, San Diego, CA, 92101, United States
The inaugural Spatial Biology for Immuno-Oncology Summit runs at a crucial moment in time. Spurred on by technological advancement and successful case studies, spatial technologies are set to become increasingly mainstream and accessible. If you’re not already, now is the time to harness spatial technologies to power your immunotherapy research, improve your clinical trials, enhance your biomarker discovery, and streamline your therapeutic development.
Uniting researchers, technology providers, and drug developers, next January join your peers to hear the latest best-practice case studies on operationalizing technology, integrating spatial into the clinic, and developing a robust data analysis pipeline. This meeting will provide an unrivaled opportunity to solve your current spatial challenges to improve your ability to treat disease and identify drug targets in immuno-oncology.
Across 3 jam-packed days of content, led by 20+ immuno-oncology leaders, the Spatial Biology for Immuno-Oncology Summit is your only chance to discover how technologies that put omics and single-cell information in spatial context can improve your ability to treat disease and identify drug targets in immuno-oncology.
Join over 100 key industry stakeholders as they gather and leave no stone unturned to advance the application of this revolutionary technology.
To know more visit: https://bit.ly/3yYeUhw

Transdermal and Microneedle Drug Delivery
2023-01-23 - 2023-01-24 | London, UK
SAE Media Group’s 2nd Annual Conference
Transdermal and Microneedle Drug Delivery
January 23 – 24, 2023 | London, UK
www.transdermal-microneedle-delivery.co.uk/pharmajournalistel
————————————————————————-
SAE Media Group is proud to present the 2nd annual Transdermal and Microneedle Drug Delivery Conference, taking place on the 23rd to 24th January 2023.

The 2023 Transdermal and Microneedle Drug Delivery Conference will explore real world applications of microneedles in drug delivery and strategies for advanced and user-centric device design. Regulation of transdermal delivery systems will be another key theme addressed, in combination with clinical trial optimization. Engage in the latest innovations in device design, development and formulation, with case studies from expert key opinion leaders of this rapidly accelerating space. Other key areas will be microneedle vaccines and transdermal patches for management of chronic disease.
The two-day agenda offers you peer-to-peer networking with CEO’s, Senior Vice presidents, Directors, Heads of Product Development and many more.
BENEFITS OF ATTENDING:

Engage with senior industry opinion leaders presenting their experiences and case studies in innovative device design and advanced drug product formulation
Gain insights from notified body and competent authority representatives addressing key regulatory requirements
Understand how to optimize your lifecycle management strategy for a commercially successful device
Explore and benchmark against industry advances in device design through case studies and real-world examples

WHO SHOULD ATTEND:

Drug-Delivery Device Developers
Microneedle Device Developers
Transdermal Delivery Developers
Microarray Patch Developers
Medical Device Engineers
Primary Packaging Material Designers
Secondary Packagers
Smart Device Developers
Training Device Developers
Device-Safety Solution Providers
Drug Developers
Transdermal Drug Product Developers

EARLY-BIRD RATES:

BOOK BY 30TH SEPTEMBER AND SAVE £400

Registrations can be made on the event website at: www.transdermal-microneedle-delivery.co.uk/
Targeted Keywords
Transdermal and Microneedle Drug Delivery, transdermal, drug development, regulatory guidelines, pharmaceutical industry, drug delivery, therapeutic sectors, vaccines, Parenteral administration, combination products, primary packaging, sterile injectables, connectivity, human factors, autoinjectors

2nd Annual mRNA-Based Therapeutics Summit Europe
2023-01-24 - 2023-01-26 | TBC – Berlin, Germany
The 2nd Annual mRNA-Based Therapeutics Summit Europe is the only end-to-end mRNA-dedicated meeting in Europe and the largest gathering for mRNA professionals outside of the United States.
Built with biopharmaceutical industry insights, this meeting will unite KOLs from Europe and the rest of the world to delve into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity, delivery & efficacy for immuno-oncology, infectious diseases and beyond.
Hear from 35+ pioneering large pharma, biotech, and academic experts who are shaping the landscape of mRNA-based therapeutics and discover how they are addressing the major challenges facing the industry.
With more companies investing in their tools and technologies to innovate processes and technologies to address key challenges such as sequence optimization, cell-specific payload expression, and durability, there has never been a more pivotal time to join European biopharma experts and discuss the following topics.
-Emerging cell-enhancing or protein replacement therapies based on mRNA
-Optimization of analytical and quality control protocols
-Durability, accessibility and immunogenicity challenges of mRNA therapeutics and vaccines
-Enhancement of formulation, process development and manufacturing processes
-Need for clear regulatory path to support the technology whilst enabling speed to market
To learn more, download your copy of the full event guide including all speakers and their session details: https://ter.li/tholw0

DDR Inhibitors Summit 2023
2023-01-24 - 2023-01-26 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The 6th DDR Inhibitors Summit is taking place in-person for the first time in 3 years in Boston, MA this January 24 – 26, 2023.
The DNA damage response inhibitor space only continues to grow, with progress being accelerated by a shift in focus onto next-generation targets like PolQ and WRN, moving forward from monotherapies through combining targets and exploiting sensitivity caused by DDRis to enhance other therapies like radiotherapy.
The scope of this year’s meeting is to bring together leading minds in DDRi drug development to exploring these strategies and aim to address issues related to emerging DDR inhibitor resistance and maximizing efficacy, as well as addressing the biggest challenge in the space right now, toxicity.
The 3-day meeting will consist of a comprehensive overview of the DDR space, with over 30+ world class speakers sharing insights preclinical updates, progress in the clinic, solutions to overcoming toxicity and improving patient selection.
Don’t miss out on hearing from the best in the field on how to overcome toxicity and resistance during drug design as well as in the clinic, to maximize efficacy and propel your DDR inhibitors to success.
To know more visit: https://ter.li/40qr50

2nd HFpEF & HCM Drug Discovery & Development Summit
2023-01-24 - 2023-01-26 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
The 2nd HFpEF & HCM Drug Discovery & Development Summit is the definitive industry forum dedicated to propelling drug discovery and development across emerging therapeutics including cell and gene therapies and the implementation of precision medicine.

Shake hands with industry pioneers prioritizing the development of therapeutic treatments to complement the new standard of care with SGLT2 inhibitors and understand how you can leverage advances in biomarkers for early detection of drug efficacy and clinical trial updates to inform your strategic decisions.
Join 80+ biopharma experts in research, cardiovascular, rare disease and precision medicine as they analyze the HFpEF patient population and translational drug development pathway to achieve new commercially viable and clinically accepted therapeutics.
To know more visit: https://bit.ly/3EjK5H3

3rd TGF-β for Immuno-Oncology Drug Development Summit
2023-01-30 - 2023-02-01 | Marines Memorial Club and Hotel, 609 Sutter St, San Francisco, CA, 94102, United States
Exploit Understanding of TGF-β Biology, Harness Clinically Validated Biomarkers & Advance Safe & Efficacious Clinical Programs for Maximal Therapeutics Benefit in Immuno-Oncology.
In the past year alone, the field has learnt valuable lessons from the clinical trials and from the wider TGF-β field that will equip the immuno-oncology field with the knowledge needed to supercharge future TGF-β monotherapy or combinational therapeutics for precision medicine.
From uncovering the effects and production of TGF-β in immune, tumor and stromal cells to exploring predictive and pharmacodynamic TGF-β biomarkers for patient identification and assessing the clinical challenges that led to recent clinical failures, the 3rd TGF-β for Immuno-Oncology Drug Development Summit is your one-stop-shop dedicated to harnessing you with the knowledge to unlock the potential of successfully targeting TGF-β.
Tailored with 18+ senior leaders, the 2023 meeting will be taking place in-person for the first time – don’t miss your chance to be in the room for your comprehensive guide on TGF-β in immuno-oncology!
Whether you are new to this field or a seasoned expert, this meeting will provide you with the must-know takeaways from the basic biology to biomarkers to clinical trial design to overcome the clinical setbacks and produce a blockbuster TGF-β therapeutic.
To know more visit: https://ter.li/cjnpgy
